Hormone Replacement Therapy Appears to Be Safe After Prophylactic Adnexectomy in Premenopausal BRCA1/BRCA2 Mutation Carriers. Reaction to the 'Letter to readers' in Hereditary Cancer in Clinical Practice, 2005, 3 (2)

In writing the letter to readers of our journal three months ago I was asking about opinions concerning the use of hormone replacement therapy (HRT) in BRCA1/2 carriers after prophylactic adnexectomy, because at that time it was practically impossible to present evidence-based recommendations. Actua...

Full description

Saved in:
Bibliographic Details
Published in:Hereditary cancer in clinical practice 2005-09, Vol.3 (3), p.87-93, Article 87
Main Author: Lubi?ski, Jan
Format: Article
Language:English
Subjects:
BRCA mutations
Breast cancer
Care and treatment
Diagnosis
Genetic aspects
Health aspects
Hormone therapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In writing the letter to readers of our journal three months ago I was asking about opinions concerning the use of hormone replacement therapy (HRT) in BRCA1/2 carriers after prophylactic adnexectomy, because at that time it was practically impossible to present evidence-based recommendations. Actually, most of the responses we have received have been opinions. It is important to recognise that the situation is now much clearer with studies performed by Tim Rebbeck et al which are to be published in the Journal of Clinical Oncology. The following responses have been received:
ISSN:1897-4287
1731-2302
1897-4287
DOI:10.1186/1897-4287-3-3-87